Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy

References

• Hellmann A. Myeloproliferative syndromes: diagnosis and therapeutic options. Polskie Archiwum Medycyny Wewnetrznej 2008;118:756–760.
   PubMedGoogle Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098–4103.
   PubMed Web of Science ®Google Scholar
• Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012;158:453–471.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60: 233–245.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Leitch HA, Chase JM, Goodman TA, et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol 2010;28:40–48.
   PubMed Web of Science ®Google Scholar
• Brown K, Subramony C, May W, et al. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy. J Pediatr Hematol Oncol 2009;31:309–312.
   PubMed Web of Science ®Google Scholar
• Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol 2009;122:174–183.
   PubMed Web of Science ®Google Scholar
• Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858–863.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001;38(Suppl. 1):57–62.
   PubMed Web of Science ®Google Scholar
• Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38(Suppl. 1):30–36.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76–79.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–573.
   PubMed Web of Science ®Google Scholar
• Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229–1236.
   PubMed Web of Science ®Google Scholar
• Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009;82:454–457.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458–465.
   PubMed Web of Science ®Google Scholar
• Harvey RD. Myelodysplastic syndromes and the role of iron overload. Am J Health Syst Pharm 2010;67(Suppl. 2):S3–S9.
   Web of Science ®Google Scholar
• Tesch H, Ihling C. Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report. Onkologie 2013;36:205–208.
   PubMed Web of Science ®Google Scholar
• Di Tucci AA, Murru R, Alberti D, et al. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007;78:540–542.
   PubMed Web of Science ®Google Scholar
• Lisette del C, Enrico B, Eleonora A, et al. Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis. Case Rep Hematol 2013;2013:520712.
   PubMedGoogle Scholar
• Mehta J, Wang H, Fryzek JP, et al. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma 2014;55:2368–2374.
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics MarketScan Research Database. Available from: http://truvenhealth.com/your-healthcare-focus/analytic-research/marketscan-research-databases
   Google Scholar
• IMS LifeLink PharMetrics Plus™ – U.S. Available from: www.imshealth.com/deployedfiles/imshealth/Global/Content/Home%20Page%20Content/Real-World%20insights/IMS_Lifelink_pharmetrics_Plus.pdf
   Google Scholar
• Gale RP, Barosi G, Barbui T, et al. What are RBC-transfusion-dependence and -independence? Leuk Res 2011;35:8–11.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905–911.
   PubMed Web of Science ®Google Scholar
• Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990;76:148–149.
   PubMed Web of Science ®Google Scholar
• Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008;120:70–74.
   PubMed Web of Science ®Google Scholar
• Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996;51:243–244.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012;97: 1364–1371.
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010;34:864–870.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol 2001;38(Suppl. 1):69–72.
   PubMed Web of Science ®Google Scholar
• Inati A, Khoriaty E, Musallam KM, et al. Iron chelation therapy for patients with sickle cell disease and iron overload. Am J Hematol 2010;85:782–786.
   PubMed Web of Science ®Google Scholar
• Bennett JM;MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008;83:858–861.
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Gattermann N, Lee JW, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus 2013;11:108–122.
   PubMed Web of Science ®Google Scholar
• Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(Suppl. 3):S7–S9.
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 2007;110:80A–81A.
   Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574–578.
   PubMed Web of Science ®Google Scholar